Otsuka Pharmaceutical announced on Dec. 2, 2014 that it had reached an agreement in which Otsuka America, its US subsidiary, would acquire Avanir Pharmaceuticals for $3.5 billion. Avanir, a biopharmaceutical company specializing in central nervous system (CNS) diseases, is the US-based manufactuOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.